RE: Prelude to what ?17 May 2016 18:14
"The Directors have considered the cash position in the context of going concern and their conclusions are set out in the Financial review (page 31), the Directors' report (page 69) and in Note 1 to the consolidated financial statements (page 81)" [all three state the same text]
The Directors estimate that the cash held by the Group together with known and probable receivables will be sufficient to support the current level of activities into the third quarter of 2016. This estimate does not include the potential benefit of any upfront receipts from further contracts for process development and bioprocessing services or from licencing-out the Group’s intellectual property, and the Directors are therefore continuing to explore other sources of finance available to the Group. The Directors have confidence that they will be able to secure sufficient cash inflows for the Group to continue its activities for not less than 12 months from the date of approval of these financial statements, and have therefore prepared the financial statements on a going concern basis. However, because the additional finance is not committed at the date of approval of these financial statements, these circumstances represent a material uncertainty which may cast significant doubt on the Group’s ability to continue as a going concern. "